マーケットレポート詳細

細胞治療および遺伝子治療：世界市場2026年予測

Global Cell and Gene Therapy Market

出版元：BCC Research 　 出版元について
発行年：2022年1月
定価 ：Single User License(1名様ライセンス)US$5,500(米国ドル)/　2-5 Users License $6,600/　Site License $7,920/　Enterprise License $9,504
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算（お見積り日TTSレート）となります。
納品形態：PDF by Email
当調査レポートは英文108ページになります。
商品コード：BCC365

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

細胞治療および遺伝子治療の世界市場規模は2021年で41億ドル、2026年に174億ドル、市場の平均年成長率は33.6%に達すると予測されています。
市場の成長要因として、近年の臨床試験の大幅な増加、多くの利害関係者からの投資の増加、希少疾病や慢性疾患に対する個別化医療への注目の高まりが挙げられます。細胞治療および遺伝子治療の臨床試験および承認の数は、今後数年間で増加すると予想されます。FDAは、2025年までには年間10〜20の細胞治療および遺伝子治療製品を承認するようになる、と予測しています。各種取り組みの強化を経てもなお、細胞治療および遺伝子治療は依然として実験医学であり、より広い応用のために追加の研究が必要です。しかしながら、ベクター生物学、ドラッグデリバリー技術、CRISPRなどの遺伝子編集技術の最近の進歩は、研究を推進することが期待されており、より多くの医薬品の上市に貢献する可能性があります。

当レポートでは、細胞治療および遺伝子治療の市場/技術的背景、市場ダイナミクス、各種セグメント別市場分析(治療タイプ別、ベクタータイプ別、製品別、治療領域別、国地域別)、COVID-19の影響、パイプライン分析、競合状況、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

◆イントロダクション

・調査目的
・調査対象
・調査手法

◆サマリーと調査ハイライト

◆市場/技術的背景

・細胞治療および遺伝子治療の概要

◆市場ダイナミクス

・市場ダイナミクス（ドライバー、障壁、機会）

◆細胞治療および遺伝子治療市場、治療タイプ別

・細胞治療
・遺伝子改変細胞治療
・遺伝子治療
※治療タイプ別に市場予測データ掲載（-2026）

◆遺伝子改変細胞治療および遺伝子治療市場、ベクタータイプ別

・アデノ随伴ウイルス（AAV）ベクター
・レトロウイルスベクター
・レンチウイルスベクター
・その他
※ベクタータイプ別に市場予測データ掲載（-2026）

◆細胞治療および遺伝子治療市場、製品別

・Zolgensma
・Yescarta
・Kymriah
・Zynteglo
・Maci
・Tecartus
・Epicel
・その他
※製品別に市場予測データ掲載（-2026）

◆細胞治療および遺伝子治療市場、治療領域別

・希少疾患
・腫瘍科
・血液科
・眼科
・神経科
・その他治療領域
※用途別に市場予測データ掲載（-2026）

◆細胞治療および遺伝子治療市場、国地域別

米国
・北米、カナダ、メキシコ
欧州
・ドイツ、英国、フランス
・その他欧州
アジア太平洋
・日本、中国、オーストラリア
・その他アジア太平洋
その他地域
※地域別に各種セグメント別の細分化データ掲載（-2026）

◆COVID-19の影響

・アウトブレイク
・COVID-19の症状
・COVID-19の進行
・潜伏期間
・疫学

◆パイプライン分析

◆競合状況

・概要

◆細胞治療および遺伝子治療の主要企業プロフィール

AMGEN INC.
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
DENDREON PHARMACEUTICALS LLC
GILEAD SCIENCES INC.
NOVARTIS INTERNATIONAL AG
ORCHARD THERAPEUTICS PLC.
PHARMICELL CO. LTD.
SIBIONO GENETECH CO. LTD.
VERICEL CORP.

(全108頁)


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of This Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

Highlights of the Market for Cell and Gene Therapy

Chapter 3 Cell and Gene Therapy: Background and Technology

Cell and Gene Therapy Overview

Chapter 4 Market Dynamics

Market Dynamics

  • Market Drivers
  • Market Restraints
  • Market Opportunities

Chapter 5 Market Breakdown by Therapy Type

Global Market for Cell and Gene Therapy

  • Market Analysis

Cell Therapy

  • Market Size and Forecast

Gene-Modified Cell Therapy

  • Market Size and Forecast

Gene Therapy

  • Market Size and Forecast

Global Market for Gene Modified Cell Therapy and Gene Therapy by Vector Type

  • Market Analysis
  • Adeno-Associated Viral (AAV) Vectors
  • Retroviral Vectors
  • Lentiviral Vectors
  • Others

Chapter 6 Market Breakdown by Product

Global Market for Cell and Gene Therapy by Product

  • Zolgensma
  • Yescarta
  • Kymriah
  • Zynteglo
  • Maci
  • Tecartus
  • Epicel
  • Others

Chapter 7 Market Breakdown by Application

Global Market for CGTs by Application
Rare Diseases
Oncology
Hematology
Ophthalmology
Neurology
Other Therapeutic Areas

  • Cardiovascular Diseases

Chapter 8 Market Breakdown by Region

Global Market for Cell and Gene Therapy by Region
North America

  • U.S.
  • Canada
  • Mexico

Europe

  • Germany
  • U.K.
  • France
  • Rest of Europe

Asia-Pacific

  • Japan
  • China
  • Australia
  • Rest of Asia-Pacific

Rest of the World

Chapter 9 Impact of the COVID-19 Pandemic

Introduction
Outbreak
Symptoms of COVID-19
Progression of COVID-19
Incubation Period
Epidemiology

  • Global Confirmed COVID-19 Cases and Deaths
  • Collaboration Between Organizations and Governments
  • Spread of Disease
  • COVID-19 Impact on the Cell and Gene Therapy Market

Chapter 10 Pipeline Analysis

Pipeline Analysis

  • Pipeline of Supplemental Indication and Formulation Expansions
  • Drugs Pending Approval

Chapter 11 Competitive Landscape

Competitive Landscape: Overview

  • Market Share Analysis
  • Strategic Acquisitions and Collaborations

Chapter 12 Company Profiles

AMGEN INC.
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
DENDREON PHARMACEUTICALS LLC
GILEAD SCIENCES INC.
NOVARTIS INTERNATIONAL AG
ORCHARD THERAPEUTICS PLC.
PHARMICELL CO. LTD.
SIBIONO GENETECH CO. LTD.
VERICEL CORP.

Chapter 13 Appendix: List of Acronyms

List of Tables

Summary Table : Global Market for Cell and Gene Therapy, by Therapy Type, Through 2026
Table 1 : Approved Cell Therapy Products (Including Withdrawn Products)
Table 2 : Approved Gene Therapy Products (Including Withdrawn Products)
Table 3 : Total Number of New Cases and Deaths Due to Various Cancers Globally, 2020
Table 4 : Comparison of Accelerated Approvals for Various Drugs
Table 5 : Global Market for Cell and Gene Therapy, by Type, Through 2026
Table 6 : Global Market for Cell Therapy, by Region, Through 2026
Table 7 : Approved CAR-T Products, as of December 2021
Table 8 : Global Market for Gene-modified Cell Therapy, by Region, Through 2026
Table 9 : Global Market for Gene Therapy, by Region, Through 2026
Table 10 : Global Market for Gene-modified Cell Therapy and Gene Therapy, by Vector, Through 2026
Table 11 : Global Market for Cell and Gene Therapy, by Product, Through 2026
Table 12 : Global Market for CGTs, by Application, Through 2026
Table 13 : Global Market for CGTs for Rare Diseases, by Region, Through 2026
Table 14 : Global Market for CGTs for Oncology, by Region, Through 2026
Table 15 : Global Market for CGTs for Hematology, by Region, Through 2026
Table 16 : Global Market for CGTs for Ophthalmology, by Region, Through 2026
Table 17 : Global Market for CGTs for Neurology, by Region, Through 2026
Table 18 : Global Market for CGTs for Other Therapeutic Areas, by Region, Through 2026
Table 19 : Global Market for Cell and Gene Therapy, by Region, Through 2026
Table 20 : North American Market for CGTs, by Country, Through 2026
Table 21 : European Market for CGTs, by Country, Through 2026
Table 22 : Asia-Pacific Market for CGTs, by Country, Through 2026
Table 23 : Distribution of COVID-19 Clinical Symptoms
Table 24 : Total Number of COVID-19 Confirmed Cases and Deaths Globally, by Country, December 13, 2021
Table 25 : Total Number of Clinical Trials, by Indication, 2020
Table 26 : Key CGT Drug Candidates in Phase I Trials
Table 27 : Key CGT Drug Candidates in Phase II Trials
Table 28 : Key CGT Drug Candidates in Phase III Trials
Table 29 : Key CGT Drug Candidates in Supplemental Indication and Formulation Expansions
Table 30 : CGT Drug Awaiting Approvals
Table 31 : Blockbuster Drugs, Estimated Sales 2026
Table 32 : Novartis Acquisitions and Collaborations Portfolio, 2018-2021
Table 33 : Gilead Acquisitions and Collaborations Portfolio
Table 34 : Amgen Inc.: CGT Product Portfolio
Table 35 : Bluebird Bio Inc.: CGT Product Portfolio
Table 36 : Bristol-Myers Squibb Co.: CGT Product Portfolio
Table 37 : Dendreon Pharmaceuticals LLC: CGT Product Portfolio
Table 38 : Gilead Sciences Inc.: CGT Product Portfolio
Table 39 : Novartis: CGT Product Portfolio
Table 40 : Orchard Therapeutics plc: CGT Product Portfolio
Table 41 : Pharmicell Co. Ltd.: CGT Product Portfolio
Table 42 : Sibiono Genetech Co. Ltd.: CGT Product Portfolio
Table 43 : Vericel Corp.: CGT Product Portfolio
Table 44 : Acronyms Used in This Report

List of Figures

Summary Figure : Global Market for Cell and Gene Therapy, by Therapy Type, 2019-2026
Figure 1 : Various Gene Therapy Strategies
Figure 2 : Administration Routes in Gene Therapy
Figure 3 : Global Market Shares of Cell and Gene Therapy, by Therapy Type, 2020
Figure 4 : Global Market for Cell Therapy, by Region, 2019-2026
Figure 5 : Global Market for Gene Modified Cell Therapy, by Region, 2019-2026
Figure 6 : Global Market Shares of Gene-modified Cell Therapy and Gene Therapy, by Vector Type, 2020
Figure 7 : Global Market for Adeno-Associated Viral Vectors in Gene-Modified Cell Therapy and Gene Therapy, 2019-2026
Figure 8 : Global Market for Retrovirus Vector in Gene-Modified Cell Therapy and Gene Therapy, 2019-2026
Figure 9 : Global Market for Lentiviral Vectors in Gene-Modified Cell Therapy and Gene Therapy, 2019-2026
Figure 10 : Global Market for Other Types of Vectors Used in Gene-modified Cell Therapy and Gene Therapy, 2019-2026
Figure 11 : Global Market Shares of Cell and Gene Therapy, by Product, 2020
Figure 12 : Global Market for Zolgensma, 2019-2026
Figure 13 : Global Market for Yescarta, 2019-2026
Figure 14 : Global Market for Kymriah, 2019-2026
Figure 15 : Global Market for Zynteglo, 2019-2026
Figure 16 : Global Market for Maci, 2019-2026
Figure 17 : Global Market for Tecartus, 2019-2026
Figure 18 : Global Market for Epicel, 2019-2026
Figure 19 : Global Market for Other Products, 2019-2026
Figure 20 : Global Market Shares of CGTs, by Application, 2020
Figure 21 : Global Market Shares of CGTs, by Region, 2020
Figure 22 : North American Market Shares of CGTs, by Country, 2020
Figure 23 : U.S. Market for CGTs, 2019-2026
Figure 24 : Canadian Market for CGTs, 2019-2026
Figure 25 : Mexican Market for CGTs, 2019-2026
Figure 26 : European Market Shares of CGTs, by Country, 2020
Figure 27 : German Market for CGTs, 2019-2026
Figure 28 : U.K. Market for CGTs, 2019-2026
Figure 29 : French Market for CGTs, 2019-2026
Figure 30 : Rest of European Market for CGTs, 2019-2026
Figure 31 : Asia-Pacific Market Shares of CGTs, by Country, 2020
Figure 32 : Japanese Market for CGTs, 2019-2026
Figure 33 : Chinese Market for CGTs, 2019-2026
Figure 34 : Australian Market for CGTs, 2019-2026
Figure 35 : Rest of Asia-Pacific Market for CGTs, 2019-2026
Figure 36 : Rest of the World Market for CGTs, 2019-2026
Figure 37 : Total Number of Clinical Trials, by Phase, 2020
Figure 38 : Number of CGT Developers, by Region, 2020
Figure 39 : Global Market Shares of CGT Drugs, by Company, 2020
Figure 40 : Amgen Inc.: Annual Revenue, 2018-2020
Figure 41 : Amgen Inc.: Revenue Share, by Region, 2020
Figure 42 : Bluebird Bio Inc.: Annual Revenue, 2019 and 2020
Figure 43 : Bristol-Myers Squibb Co.: Annual Revenue, 2019 and 2020
Figure 44 : Bristol-Myers Squibb Co.: Sales Shares, by Region, 2020
Figure 45 : Gilead Sciences Inc.: Annual Revenue, 2018-2020
Figure 46 : Gilead Sciences Inc.: Sales Share, by Region, 2020
Figure 47 : Gilead Sciences Inc.: Sales Share, by Business Segment, 2020
Figure 48 : Gilead Sciences Inc.: Sales Division, Cell Therapy Products, 2020
Figure 49 : Novartis: Annual Revenue, 2018-2020
Figure 50 : Novartis: Innovative Medicines Segment Revenue Share, by Region, 2020
Figure 51 : Orchard Therapeutics plc: Annual Revenue, 2019 and 2020
Figure 52 : Pharmicell Co. Ltd.: Annual Revenue, 2018-2020
Figure 53 : Vericel Corp.: Annual Revenue, 2018–2020
Figure 54 : Vericel Corp.: Revenue Share, by Product Category, 2020


△ 一番上に戻る